-
公开(公告)号：US20230340423A1
公开(公告)日：2023-10-26
申请号：US18010740
申请日：2021-07-07
申请人： CODAGENIX INC.
发明人： John Robert Coleman , Steffen Mueller , Chen Yang , Ying Wang , Yutong Song
CPC分类号： C12N7/00 , C12Q1/70 , C12Q1/686 , C12N2770/20021 , C12N2770/24121
摘要： The present invention describes methods of generating a modified viral genome, producing infectious RNA, and generating modified viruses. The modified viral genome, infections RNA, and modified viruses comprise deoptimized nucleic acids; for example, codon-pair deoptimized or synonymous codon deoptimized. These modified viruses can be used in vaccines and methods of eliciting a protective immune response.
-
公开(公告)号：US20240299533A1
公开(公告)日：2024-09-12
申请号：US18574973
申请日：2022-06-30
发明人： Steffen Mueller , John Robert Coleman , Ying Wang , Chen Yang , Yutong Song
IPC分类号： A61K39/215 , A61K9/00 , A61K39/00 , A61P31/14 , C07K14/005 , C12N7/00
CPC分类号： A61K39/215 , A61K9/0043 , A61P31/14 , C07K14/005 , C12N7/00 , A61K2039/5254 , A61K2039/543 , A61K2039/545 , C12N2770/20021 , C12N2770/20022 , C12N2770/20034
摘要： Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.
-
3.发明申请公开(公告)号：US20190233476A1
公开(公告)日：2019-08-01
申请号：US16335099
申请日：2017-09-22
IPC分类号： C07K14/08 , A61K39/155 , A61K9/00 , A61P31/20
摘要： Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
-
公开(公告)号：US20240165217A1
公开(公告)日：2024-05-23
申请号：US18283130
申请日：2022-04-08
申请人： CODAGENIX INC.
CPC分类号： A61K39/12 , A61P37/02 , A61K2039/5254 , A61K2039/543 , A61K2039/545 , A61K2039/575 , C12N2760/18534 , C12N2760/18562 , C12N2760/18571
摘要： The present invention provides for methods of vaccination and eliciting a IgA immune response and cellular immune response, including T-cell immune response by administering a deoptimized respiratory syncytial virus (RSV).
-
公开(公告)号：US20230117167A1
公开(公告)日：2023-04-20
申请号：US17794862
申请日：2021-01-27
发明人： Steffen Mueller , John Robert Coleman , Ying Wang , Chen Yang
IPC分类号： C07K14/005 , A61K39/215 , A61P31/14
摘要： Described herein are modified SARS-CoV-2 coronaviruses. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 coronavirus infection, preventing a SARS-CoV-2 coronavirus infection, eliciting and immune response, or treating a SARS-CoV-2 coronavirus infection.
-
6.发明申请公开(公告)号：US20210188920A1
公开(公告)日：2021-06-24
申请号：US17008025
申请日：2020-08-31
IPC分类号： C07K14/08 , A61K39/155 , C12N7/04 , A61P31/20 , A61K9/00
摘要： Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
-
7.发明授权公开(公告)号：US12054519B2
公开(公告)日：2024-08-06
申请号：US17851905
申请日：2022-06-28
CPC分类号： C07K14/08 , A61K9/0019 , A61K9/0043 , A61K39/155 , A61P31/20 , C12N7/04 , C12N2760/00021 , C12N2760/00034 , C12N2760/00062
摘要： Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
-
公开(公告)号：US20220347285A1
公开(公告)日：2022-11-03
申请号：US17621125
申请日：2020-06-23
申请人： CODAGENIX INC.
摘要： The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.
-
9.发明申请公开(公告)号：US20220340619A1
公开(公告)日：2022-10-27
申请号：US17851905
申请日：2022-06-28
IPC分类号： C07K14/08 , A61K39/155 , C12N7/04 , A61P31/20 , A61K9/00
摘要： Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
-
10.发明申请公开(公告)号：US20210228705A1
公开(公告)日：2021-07-29
申请号：US16769102
申请日：2018-12-21
申请人： CODAGENIX INC.
发明人： John Robert Coleman , Steffen Mueller , Chen Yang , Ying Wang , Charles Stauft
IPC分类号： A61K39/13 , A61K39/145 , C12N7/00
摘要： The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.016 秒)
